Calithera Biosciences (NASDAQ:CALA – Get Free Report) is expected to announce its resultson Tuesday, November 17th. Analysts expect Calithera Biosciences to announce earnings of ($5.5188) per share and revenue of $0.48 million for the quarter.
Calithera Biosciences Stock Performance
Calithera Biosciences has a 52-week low of $0.00 and a 52-week high of $0.00.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc was a clinical-stage biotechnology company focused on developing small-molecule therapies that target cancer metabolism. The company’s research centered on metabolic pathways that tumors use to support growth and survival, with the goal of improving outcomes for patients with cancer.
Its lead investigational product was telaglenastat (CB-839), an oral inhibitor of glutaminase, an enzyme involved in glutamine metabolism. Calithera evaluated telaglenastat in combination with other treatments for cancers including renal cell carcinoma, triple-negative breast cancer and hematologic malignancies.
Recommended Stories
- Five stocks we like better than Calithera Biosciences
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
